Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca announced the US FDA approval of Calquence in combination with bendamustine and rituximab for previously untreated mantle cell lymphoma (MCL) patients, marking the first BTK inhibitor approved for first-line MCL treatment. This approval, based on ECHO Phase III trial results, enhances AstraZeneca’s position in oncology by offering a new treatment option for a rare and aggressive cancer, thus potentially transforming MCL patient care and reinforcing Calquence as a key therapy in blood cancers.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
YTD Price Performance: 1.72%
Average Trading Volume: 2,748,333
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £164.8B
See more data about AZN stock on TipRanks’ Stock Analysis page.
